# Novo Nordisk shares rose 5.8% by 0913 GMT, marking the highest daily increase this year.

*biotech · news · 2026-05-06 · Devdiscourse*

## Key points

- Novo Nordisk's Wegovy pill generated 2.26 billion crowns in sales, nearly double analyst expectations.
- Novo now expects 2024 sales and profit to decline by 4–12%, a modest improvement over previous guidance.
- Wegovy pill prescriptions surpassed 2 million since January, marking the largest GLP-1 launch in U.S. history.
- Over half of U.S. Wegovy sales are now self-pay, up from 10% a year earlier.
- Lilly's Foundayo FDA approval in April ended Wegovy's status as the only U.S. oral obesity pill.

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** Denmark, United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/business/3898468-novo-nordisks-new-weight-loss-pill-boosts-profits-amid-intense-competition)

---

Canonical: https://newsio.io/n/f94fd732-a26f-4afd-a182-054b59b167af/novo-nordisk-shares-rose-5-8-by-0913-gmt-marking-the-highest-daily-increase-this
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works